Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study

Oncotarget(2022)10.18632/oncotarget.28178Source: DataRank Database

Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study is a research paper published in Oncotarget (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.47)OA: goldTopics (38)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Hillevi Bauer,Trang H. Au ORCID,Jyothi U. Menon ORCID,Sudhir Unni ORCID,Dao Tran ORCID

Live enrichment

PubMed:35111281 PMC:PMC8803368 OpenAlex:https://openalex.org/W4210553064

NCATS NIH HHS

Grant: UL1 TR002494

NCATS NIH HHS

Grant: UL1 TR002538

NCI NIH HHS

Grant: P30 CA076292

National Institutes of Health

Grant: 3UL1TR002538-01S1

Utah Center for Clinical and Translational Science

National Institutes of Health

Grant: 1TL1TR002493-01

NRSA Training Core

National Institutes of Health

Grant: 3UL1TR002494-02S1

University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)

FWCI

0.47

Citation Percentile

0.6%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.oncotarget.com/article/28178/pdf/

publisherhttps://www.oncotarget.com/article/28178/pdf/

publisherhttps://www.oncotarget.com/lookup/doi/10.18632/oncotarget.28178

journalhttps://doi.org/10.18632/oncotarget.28178

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35111281

Fields of Study

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment03 medical and health sciences0302 clinical medicine

MeSH Terms

Carcinoma, Non-Small-Cell LungHumansLung NeoplasmsMutationProspective StudiesBiomarkers, TumorCohort StudiesSurvival AnalysisReceptor Protein-Tyrosine KinasesB7-H1 AntigenErbB Receptors

Keywords

MedicineInternal medicineLung cancerOncologyBiomarkerImmunotherapyProspective cohort studyCancerLung neoplasmaTumor BiomarkersLung NeoplasmsReceptor Protein-Tyrosine KinasesSurvival AnalysisB7-H1 AntigenCohort StudiesErbB ReceptorsCarcinoma, Non-Small-Cell LungMutationBiomarkers, TumorHumansProspective StudiesResearch Paper

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being